Your browser doesn't support javascript.
loading
Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance).
Vera Aguilera, Jesus; Rao, Ravi D; Allred, Jacob B; Suman, Vera J; Windschitl, Harold E; Kaur, Judith S; Maples, William J; Lowe, Val J; Creagan, Edward T; Erickson, Lori A; Markovic, Svetomir.
Affiliation
  • Vera Aguilera J; Mayo Clinic and Mayo Foundation, Rochester, Minnesota vera.jesus@mayo.edu.
  • Rao RD; St. Agnes Cancer Center, Fresno, California.
  • Allred JB; Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
  • Suman VJ; Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
  • Windschitl HE; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
  • Maples WJ; Mayo Clinic Jacksonville, Jacksonville, Florida.
  • Creagan ET; Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
  • Erickson LA; Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
  • Markovic S; Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
Oncologist ; 23(8): 887-e94, 2018 08.
Article in En | MEDLINE | ID: mdl-29666297
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Everolimus / Melanoma / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Everolimus / Melanoma / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2018 Type: Article